Literature DB >> 15080261

The 2001 serological survey in the Czech Republic--viral hepatitis.

V Nemecek1, J Cástková, P Fritz, A Linhartová, E Svandová, H Srámová, B Kríz.   

Abstract

Within serological surveys 2001, prevalence of markers of hepatitis viruses A (anti-HAV), B (anti-HBc, HBsAg, anti-HBs) and for the first time also C (anti-HCV) was investigated. Sera were collected in 2001 and tested by respective kits AxSYM, Abbott. HAV: 2,623 sera were tested for the presence of anti-HAV antibodies. Comparison with serological surveys of 1984 and 1996 revealed again shifts of the age prevalence curve for anti-HAV antibodies towards higher age groups corresponding to time intervals between epidemiological surveys. High prevalence rates of anti-HAV antibodies (more than 20%) were only found for the population age groups who lived in the period of high incidence of VHA, i.e. up to 1965. The prevalence of anti-HAV antibodies increased by about 5-10% in the population under 20 years of age, the increase being significant and assumingly attributable to vaccination against VHA, and remained the same as in 1996 in the age group 20-29 years. HBV: 2,568 sera were tested for the presence of anti-HBc antibodies and 76 reactive specimens were further tested for the presence of HBsAg and anti-HBs antibodies. The prevalence of anti-HBc antibodies continuously increases with age. The total prevalence of anti-HBc antibodies calculated for the Czech population is 5.59% compared to 6.95% recorded in 1996. The calculated prevalence rate of HBsAg is 0.56% and that of anti-HBs antibodies is 3.99% for the non-vaccinee population. HCV: The prevalence rate of anti-HCV antibodies was 0.2% with 6 out of 2,950 sera testing positive. Age dependence could not be assessed because of the small number of positive persons. HCV infection is known to afflict high-risk groups, likely to escape a general serological survey, rather than the normal population.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15080261

Source DB:  PubMed          Journal:  Cent Eur J Public Health        ISSN: 1210-7778            Impact factor:   1.163


  5 in total

1.  Seroepidemiology of hepatitis A and hepatitis B virus in Luxembourg.

Authors:  J Mossong; L Putz; S Patiny; F Schneider
Journal:  Epidemiol Infect       Date:  2006-01-25       Impact factor: 2.451

2.  The prevalence of hepatitis C virus infection and its related risk factors among the rural population of fars province, southern iran.

Authors:  Mohammad Reza Fattahi; Alireza Safarpour; Masood Sepehrimanesh; Seyed Mohammad Kazem Hosseini Asl; Faezeh Mohamaddoust
Journal:  Hepat Mon       Date:  2015-02-06       Impact factor: 0.660

3.  Prevalence of hepatitis C virus in adult population in the Czech Republic - time for birth cohort screening.

Authors:  Roman Chlibek; Jan Smetana; Renata Sosovickova; Peter Gal; Petr Dite; Vlasta Stepanova; Lenka Pliskova; Stanislav Plisek
Journal:  PLoS One       Date:  2017-04-13       Impact factor: 3.240

4.  Expression of Biliverdin Reductase A in peripheral blood leukocytes is associated with treatment response in HCV-infected patients.

Authors:  Iva Subhanova; Lucie Muchova; Martin Lenicek; Hendrik J Vreman; Ondrej Luksan; Kristyna Kubickova; Miluse Kreidlova; Tomas Zima; Libor Vitek; Petr Urbanek
Journal:  PLoS One       Date:  2013-03-11       Impact factor: 3.240

Review 5.  Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening.

Authors:  Susan J M Hahné; Irene K Veldhuijzen; Lucas Wiessing; Tek-Ang Lim; Mika Salminen; Marita van de Laar
Journal:  BMC Infect Dis       Date:  2013-04-18       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.